Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs FLOLIPID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Reduction of elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C in patients with primary hyperlipidemia (Fredrickson type IIa and IIb) or mixed dyslipidemia,Reduction of elevated TG in patients with hypertriglyceridemia (Fredrickson type IV),Treatment of primary dysbetalipoproteinemia (Fredrickson type III) when diet is not sufficient,Reduction of total-C and LDL-C in patients with homozygous familial hypercholesterolemia,Prevention of cardiovascular events in patients with high risk of coronary heart disease
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites.
Approximately 50% bound to plasma proteins, primarily albumin.
More than 99% bound, primarily to albumin.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
For GFR 30 to <60 m L/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 m L/min/1.73 m²: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning).,Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment.,Increased risk of diabetes mellitus: Small increase in fasting glucose and Hb A1c.,Interstitial lung disease: Rare cases reported.,Use with caution in patients with predisposing factors for renal impairment.
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Hypersensitivity to any component of Flolipid,Active liver disease or unexplained persistent elevations of serum transaminases,Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone),Concomitant use of gemfibrozil, cyclosporine, or danazol,Pregnancy and breastfeeding,Women of childbearing potential unless using effective contraception
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Grapefruit juice may modestly increase pitavastatin exposure; limit to small amounts (≤8 oz per day). No other significant food interactions; can be taken with or without food. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Breastfeeding is contraindicated during rosuvastatin therapy. M/P ratio: unknown. Rosuvastatin is excreted in rat milk; human data absent. Potential for serious adverse reactions in nursing infants.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
FLOLIPID should be discontinued upon pregnancy detection. No dose adjustments in pregnancy as use is contraindicated. Pharmacokinetic changes in pregnancy may reduce rosuvastatin exposure, but safety data insufficient to recommend resuming.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Flolipid (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug interactions; monitor for myopathy and hepatotoxicity; avoid in active liver disease; dose adjustment needed with renal impairment (Cr Cl <30 m L/min); no significant food effect, but grapefruit juice may modestly increase exposure; consider in patients with statin intolerance due to fewer CYP-mediated interactions.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Take Flolipid at the same time each day, with or without food.,Avoid consuming large amounts of grapefruit juice; a small glass (8 oz) is acceptable.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you develop jaundice, dark urine, or abdominal pain (signs of liver problems).,Continue a heart-healthy diet and exercise while taking this medication.,Do not double the dose if you miss one; take the next dose at the usual time.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs FLOLIPID, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. FLOLIPID is a HMG-CoA Reductase Inhibitor (Statin) that works by Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and FLOLIPID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of FLOLIPID is: Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and FLOLIPID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. FLOLIPID is classified as Category C. FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.